Patents by Inventor Katherine L. Worledge

Katherine L. Worledge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
    Patent number: 7261891
    Abstract: Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to proinflammatory cytokines (such as IL-6 and TNF) are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of colitis, including Crohn's disease.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: August 28, 2007
    Assignee: Promega Corporation
    Inventors: John A. Kink, Katherine L. Worledge, Douglas C. Stafford
  • Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
    Patent number: 6663864
    Abstract: Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to proinflammatory cytokines (such as IL-6 and TNF) are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of colitis, including Crohn's disease.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: December 16, 2003
    Assignee: Promega Corp.
    Inventors: John A. Kink, Katherine L. Worledge, Douglas C. Stafford
  • Prevention and treatment of inflammatory bowel disease
    Patent number: 6395273
    Abstract: Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to TNF are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of colitis.
    Type: Grant
    Filed: June 10, 1998
    Date of Patent: May 28, 2002
    Assignee: Promega Corporation
    Inventors: John A. Kink, Katherine L. Worledge, Douglas C. Stafford
  • Prevention and treatment of necrotizing enterocolitis
    Publication number: 20020031516
    Abstract: Methods are described for preventing and treating necrotizing enterocolitis in animals, including humans. Antibodies directed to PAF and/or TNF are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of necrotizing enterocolitis, which is a major life-threatening illness in neonates worldwide.
    Type: Application
    Filed: April 10, 2001
    Publication date: March 14, 2002
    Applicant: Promega Corporation
    Inventors: John A. Kink, Katherine L. Worledge
  • Prevention and treatment of necrotizing enterocolitis
    Patent number: 6214343
    Abstract: Methods are described for preventing and treating necrotizing enterocolitis in animals, including humans. Antibodies directed to PAF and/or TNF are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of necrotizing enterocolitis, which is a major life-threatening illness in neonates worldwide.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: April 10, 2001
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: John A. Kink, Katherine L. Worledge